ES2609813T3 - Antígeno nuevo asociado con la neovasculatura de metástasis tumorales - Google Patents

Antígeno nuevo asociado con la neovasculatura de metástasis tumorales Download PDF

Info

Publication number
ES2609813T3
ES2609813T3 ES12195343.4T ES12195343T ES2609813T3 ES 2609813 T3 ES2609813 T3 ES 2609813T3 ES 12195343 T ES12195343 T ES 12195343T ES 2609813 T3 ES2609813 T3 ES 2609813T3
Authority
ES
Spain
Prior art keywords
antibody
domain
amino acid
acid sequence
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12195343.4T
Other languages
English (en)
Spanish (es)
Inventor
Dario Neri
Jascha Rybak
Christoph Rösli
Alessandra Villa
Giovanni Neri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philogen SpA
Original Assignee
Philogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen SpA filed Critical Philogen SpA
Application granted granted Critical
Publication of ES2609813T3 publication Critical patent/ES2609813T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
ES12195343.4T 2007-04-02 2008-03-31 Antígeno nuevo asociado con la neovasculatura de metástasis tumorales Active ES2609813T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90958007P 2007-04-02 2007-04-02
US909580P 2007-04-02
US94856407P 2007-07-09 2007-07-09
US948564P 2007-07-09

Publications (1)

Publication Number Publication Date
ES2609813T3 true ES2609813T3 (es) 2017-04-24

Family

ID=39791007

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12195343.4T Active ES2609813T3 (es) 2007-04-02 2008-03-31 Antígeno nuevo asociado con la neovasculatura de metástasis tumorales
ES08737486T Active ES2402171T3 (es) 2007-04-02 2008-03-31 El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08737486T Active ES2402171T3 (es) 2007-04-02 2008-03-31 El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales

Country Status (12)

Country Link
US (5) US8263041B2 (enExample)
EP (2) EP2653478B1 (enExample)
JP (2) JP5221641B2 (enExample)
KR (1) KR101515243B1 (enExample)
CN (2) CN101687923B (enExample)
AU (1) AU2008234615B2 (enExample)
BR (1) BRPI0809989B8 (enExample)
CA (1) CA2682851C (enExample)
EA (2) EA036322B1 (enExample)
ES (2) ES2609813T3 (enExample)
MX (1) MX2009010639A (enExample)
WO (1) WO2008120101A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817005B2 (ja) 1990-06-29 1998-10-27 スズキ株式会社 エンジン用オーバヒート検出装置
MX2009010639A (es) 2007-04-02 2009-10-23 Philogen Spa Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
CA2691218C (en) * 2007-07-25 2018-04-24 Philogen S.P.A. An antigen associated with lung cancers and lymphomas
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
HUE050038T2 (hu) 2007-10-30 2020-11-30 Philogen Spa Rheumatoid arthritisszel kapcsolatos antigén
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
JP5548872B2 (ja) * 2010-08-26 2014-07-16 株式会社島津製作所 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法
WO2012041451A1 (en) 2010-09-29 2012-04-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
ES2706428T3 (es) 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
US9695232B2 (en) 2012-10-03 2017-07-04 Philogen S.P.A. Anti-ED-A immunoconjugates for inflammatory bowel disease
SG10201805706XA (en) 2013-12-12 2018-08-30 Umc Utrecht Holding Bv Immunoglobulin-like molecules directed against fibronectin-eda
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
BR112018000909A2 (pt) 2015-07-16 2018-09-11 Philogen Spa imunoconjugados de il22
WO2018073680A1 (en) 2016-10-17 2018-04-26 Pfizer Inc. Anti-edb antibodies and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018224550A1 (en) 2017-06-07 2018-12-13 Philogen S.P.A Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
CN114206355A (zh) * 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
JOP20220035A1 (ar) 2019-08-15 2023-01-30 Janssen Biotech Inc مواد وطرق لتحسين أجزاء المتغير أحادي السلسلة
EP4185615A1 (en) 2020-07-22 2023-05-31 Philogen S.p.A. Treatment of pulmonary hypertension
CN114350518B (zh) * 2022-01-19 2023-01-13 广东乾晖生物科技有限公司 仿生肝微流控细胞培养-药物筛选芯片
EP4493210A1 (en) 2022-03-17 2025-01-22 Universitätsklinikum Jena Anti-ed-a antibodies for the treatment of pulmonary hypertension
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
FI892197A7 (fi) * 1989-05-08 1990-11-09 Locus Oy Foerfarande foer detektering av tumoerer.
US5420012A (en) * 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
EP0580859A4 (en) * 1991-03-26 1994-09-14 Otsuka Pharma Co Ltd Anti-eda monoclonal antibody
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US20030152572A1 (en) 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
YU17503A (sh) 2000-09-07 2006-05-25 Schering Aktiengesellschaft Receptor oblasti (ii) edb-fibronektina
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
PL369371A1 (en) * 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CA2523452A1 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
CA2533878A1 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US20060024722A1 (en) * 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
JP2008518609A (ja) 2004-11-09 2008-06-05 フィロゲン エスピーエー テネイシンｃに対する抗体
KR101281208B1 (ko) 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
WO2007128563A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
MX2009010639A (es) * 2007-04-02 2009-10-23 Philogen Spa Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
CA2691218C (en) * 2007-07-25 2018-04-24 Philogen S.P.A. An antigen associated with lung cancers and lymphomas
HUE050038T2 (hu) * 2007-10-30 2020-11-30 Philogen Spa Rheumatoid arthritisszel kapcsolatos antigén
EP2379116B1 (en) * 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
WO2012041451A1 (en) * 2010-09-29 2012-04-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
ES2706428T3 (es) * 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
WO2014174105A1 (en) * 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
JP2016519111A (ja) * 2013-04-26 2016-06-30 フィロゲン エスピーエー 細胞外マトリックス成分に対する抗体にコンジュゲートしたｉｌ４
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
US20130266511A1 (en) 2013-10-10
US8481684B2 (en) 2013-07-09
EP2142567A2 (en) 2010-01-13
CA2682851C (en) 2017-01-17
US20130280759A1 (en) 2013-10-24
ES2402171T3 (es) 2013-04-29
US20160083461A1 (en) 2016-03-24
JP2010523541A (ja) 2010-07-15
WO2008120101A3 (en) 2008-12-11
EA018985B1 (ru) 2013-12-30
JP5840631B2 (ja) 2016-01-06
BRPI0809989B1 (pt) 2019-10-08
EP2653478B1 (en) 2016-10-05
HK1184794A1 (zh) 2014-01-30
MX2009010639A (es) 2009-10-23
JP5221641B2 (ja) 2013-06-26
US20130040361A1 (en) 2013-02-14
BRPI0809989B8 (pt) 2021-05-25
EA036322B1 (ru) 2020-10-26
KR101515243B1 (ko) 2015-04-24
US8263041B2 (en) 2012-09-11
US9896503B2 (en) 2018-02-20
EA201301224A1 (ru) 2014-07-30
CN103275220B (zh) 2016-01-20
BRPI0809989A2 (pt) 2015-09-29
HK1140217A1 (en) 2010-10-08
CN101687923A (zh) 2010-03-31
EP2653478A1 (en) 2013-10-23
EA200970909A1 (ru) 2010-10-29
US20100247541A1 (en) 2010-09-30
AU2008234615B2 (en) 2013-10-10
KR20100016094A (ko) 2010-02-12
WO2008120101A2 (en) 2008-10-09
CN103275220A (zh) 2013-09-04
AU2008234615A1 (en) 2008-10-09
JP2013121353A (ja) 2013-06-20
CN101687923B (zh) 2013-06-19
CA2682851A1 (en) 2008-10-09
EP2142567B1 (en) 2013-01-16
US9181347B2 (en) 2015-11-10

Similar Documents

Publication Publication Date Title
ES2609813T3 (es) Antígeno nuevo asociado con la neovasculatura de metástasis tumorales
AU2020203143B2 (en) Modified antibody compositions, methods of making and using thereof
ES2632748T3 (es) Anticuerpos anti-C4.4a y usos de los mismos
JP6335796B2 (ja) Ｃｄｉｍ結合タンパク質及びその使用
BR112020012463A2 (pt) molécula de ligação ao antígeno específica de receptor órfão semelhante ao receptor tirosina quinase 1 (ror1), proteína de fusão recombinante, receptor de antígeno quimérico (car) específico de ror1, célula, sequência de ácidos nucleicos, vetor, célula hospedeira, método para preparar e uso de uma molécula de ligação ao antígeno específica, proteína de fusão recombinante ou receptor de antígeno quimérico, composição farmacêutica, método para tratamento de uma doença em um paciente que necessita de tratamento, método para avaliar a presença de um analito-alvo em uma amostra, método para imageamento de um sítio de doença em um indivíduo, método para diagnóstico de uma doença ou afecção médica em um indivíduo, anticorpo, fragmento de anticorpo ou molécula de ligação ao antígeno, kit e método para diagnóstico de um indivíduo que sofre de câncer, ou uma predisposição para o mesmo, ou para fornecer um prognóstico da afecção de um indivíduo e método para eliminar ou inibir o crescimento de uma célula que expressa ror1 in vitro ou em um paciente
CN111234020B (zh) 一种bcma结合蛋白及其制备方法和应用
EP3970798A1 (en) Sars-cov-2-nanobodies
JP2022525239A (ja) ｉＲｈｏｍ２のタンパク質バインダー
US12492249B2 (en) Antibodies and use thereof
Haus‐Cohen et al. Disruption of P‐glycoprotein anticancer drug efflux activity by a small recombinant single‐chain Fv antibody fragment targeted to an extracellular epitope
DK3166660T3 (en) SUBSTANCES AND PROCEDURES FOR USE IN PREVENTION AND / OR TREATMENT OF HUNTINGTON'S DISEASE
WO2021169982A1 (zh) 靶向EpCAM的抗体及其制备和应用
KR20250107848A (ko) 코트머단백질 복합체 서브유닛 베타2에 대한 항체
JP2017503176A (ja) 抗ｍｉｆ免疫組織化学的検査
CN115850458B (zh) 一种抗冠状病毒rbd蛋白的抗体、制备方法和应用
CN119912561B (zh) 一种抗s100蛋白的抗体及其应用
KR20200002190A (ko) 항 스핑고신-1-포스페이트 작용제, 이의 생산 방법, 및 이의 용도
WO2025122066A1 (en) Ddx3y specific binding domains
Van Fossen Employing Genetic Code Expansion Tools to Elucidate Disease Mechanisms and Generate New Therapeutics
HK40031847A (en) A bcma binding protein and method for preparation and application thereof
HK40031847B (en) A bcma binding protein and method for preparation and application thereof
JP2023519007A (ja) Ａｒｅｇに対する抗体及びその用途
EP3823994A1 (en) Novel systems for screening internalizing antibody and uses thereof
JP2016534734A (ja) 急性骨髄性白血病の診断のための抗体